NEUMORA THERAPEUTICS INC

Neumora Therapeutics (NMRA) drops 10.5% to $0.41, falling 46% this year amid concerns over its neuro‑oncology pipeline and market volatility.

Neumora Therapeutics shares dip 1.06% to $0.47, down 32.8% YTD. Learn why the clinical‑stage brain‑disease biotech’s stock lags peers and its market outlook.

Neumora Therapeutics (NMRA) slides 0.84% to $0.47, down 32% YoY, as investors eye its clinical‑stage biopharma pipeline and upcoming data releases.